Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Country-specific medical scientific information for Healthcare Professionals.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
A knowledge hub developed to provide information and education in oncology for healthcare professionals.
Browse our symposium slides and publications
Access materials presented at the annual AACR congress
Watch this animation about sequential therapy with afatinib followed by osimertinib
NSCLC in focus: information and educational resources
Learn more about our MDM2-p53 antagonist^ and other investigational compounds
*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
^This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
